PDS Biotechnology R&D Spending Growth & History (PDSB)
PDS Biotechnology's r&d spending was $19.0M for fiscal 2025.
View full PDS Biotechnology company overviewPDS Biotechnology annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $19.0M | −$3.5M | −15.69% |
| 2024 | 2024-12-31 | $22.6M | −$5.2M | −18.72% |
| 2023 | 2023-12-31 | $27.8M | −$1.7M | −5.67% |
| 2022 | 2022-12-31 | $29.4M | $18.2M | +161.50% |
| 2021 | 2021-12-31 | $11.3M | $3.3M | +42.02% |
| 2020 | 2020-12-31 | $7.9M | $1.8M | +29.92% |
| 2019 | 2019-12-31 | $6.1M | $5.3M | +634.23% |
| 2018 | 2018-12-31 | $830,744 | −$33.5M | −97.58% |
| 2017 | 2017-12-31 | $34.3M | $9.5M | +38.21% |
| 2016 | 2016-12-31 | $24.8M | $7.0M | +39.16% |
| 2015 | 2015-12-31 | $17.8M | $9.4M | +110.54% |
| 2014 | 2014-12-31 | $8.5M | $4.0M | +88.96% |
| 2013 | 2013-12-31 | $4.5M | — | — |
PDS Biotechnology quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.3M | −$947,332 | −22.49% |
| Q1 2026 | 2026-03-31 | $3.5M | −$2.4M | −40.71% |
| Q4 2025 | 2025-12-31 | $4.4M | −$124,236 | −2.74% |
| Q3 2025 | 2025-09-30 | $4.6M | −$2.2M | −32.74% |
| Q2 2025 | 2025-06-30 | $4.2M | −$314,780 | −6.95% |
| Q1 2025 | 2025-03-31 | $5.8M | −$873,165 | −13.02% |
| Q4 2024 | 2024-12-31 | $4.5M | −$2.9M | −39.33% |
| Q3 2024 | 2024-09-30 | $6.8M | $355,372 | +5.51% |
| Q2 2024 | 2024-06-30 | $4.5M | −$3.5M | −43.44% |
| Q1 2024 | 2024-03-31 | $6.7M | $860,478 | +14.72% |
| Q4 2023 | 2023-12-31 | $7.5M | −$8.7M | −53.79% |
| Q3 2023 | 2023-09-30 | $6.4M | $2.1M | +48.14% |
| Q2 2023 | 2023-06-30 | $8.0M | $4.2M | +112.80% |
| Q1 2023 | 2023-03-31 | $5.8M | $682,371 | +13.22% |
| Q4 2022 | 2022-12-31 | $16.2M | $12.8M | +376.65% |
| Q3 2022 | 2022-09-30 | $4.4M | $664,988 | +18.03% |
| Q2 2022 | 2022-06-30 | $3.8M | $997,451 | +36.08% |
| Q1 2022 | 2022-03-31 | $5.2M | $3.7M | +265.26% |
| Q4 2021 | 2021-12-31 | $3.4M | $911,556 | +36.79% |
| Q3 2021 | 2021-09-30 | $3.7M | $1.6M | +78.96% |
| Q2 2021 | 2021-06-30 | $2.8M | $1.3M | +95.46% |
| Q1 2021 | 2021-03-31 | $1.4M | −$558,622 | −28.33% |
| Q4 2020 | 2020-12-31 | $2.5M | $1.1M | +83.77% |
| Q3 2020 | 2020-09-30 | $2.1M | $226,444 | +12.34% |
| Q2 2020 | 2020-06-30 | $1.4M | −$472,709 | −25.05% |
| Q1 2020 | 2020-03-31 | $2.0M | $941,676 | +91.42% |
| Q4 2019 | 2019-12-31 | $1.3M | $1.1M | +405.10% |
| Q3 2019 | 2019-09-30 | $1.8M | $1.6M | +845.22% |
| Q2 2019 | 2019-06-30 | $1.9M | $1.7M | +1019.14% |
| Q1 2019 | 2019-03-31 | $1.0M | $828,865 | +412.09% |
| Q4 2018 | 2018-12-31 | $266,932 | −$10.6M | −97.54% |
| Q3 2018 | 2018-09-30 | $194,068 | −$6.7M | −97.19% |
| Q2 2018 | 2018-06-30 | $168,606 | −$8.8M | −98.12% |
| Q1 2018 | 2018-03-31 | $201,138 | −$7.4M | −97.35% |
| Q4 2017 | 2017-12-31 | $10.8M | $4.1M | +59.82% |
| Q3 2017 | 2017-09-30 | $6.9M | $188,668 | +2.81% |
| Q2 2017 | 2017-06-30 | $9.0M | $3.0M | +50.21% |
| Q1 2017 | 2017-03-31 | $7.6M | $2.2M | +41.95% |
| Q4 2016 | 2016-12-31 | $6.8M | $1.5M | +28.74% |
| Q3 2016 | 2016-09-30 | $6.7M | $216,531 | +3.33% |
| Q2 2016 | 2016-06-30 | $6.0M | $2.8M | +87.01% |
| Q1 2016 | 2016-03-31 | $5.3M | $2.5M | +86.22% |
| Q4 2015 | 2015-12-31 | $5.3M | — | — |
| Q3 2015 | 2015-09-30 | $6.5M | $4.1M | +169.05% |
| Q2 2015 | 2015-06-30 | $3.2M | — | — |
| Q1 2015 | 2015-03-31 | $2.9M | — | — |
| Q3 2014 | 2014-09-30 | $2.4M | — | — |
PDS Biotechnology r&d spending trends
Over the last five fiscal years, PDS Biotechnology's r&d spending increased from $7.9M to $19.0M, a change of $11.1M. The latest reported quarter, Q2 2026, shows $3.3M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review PDS Biotechnology source filings ↗